FIELD: biotechnology.
SUBSTANCE: present group of inventions relates to method of inhibiting wild-type forms and determination of mutant forms of human histone methyltransferase EZH2 – catalytic subunit of PRC2 complex, which catalyzes from mono-to trimethylation of lysine 27 on gistone H3 (H3-K27), by administering effective amount of EZH2 inhibitor and method of determining ability of response to EZH2 inhibitor in individual.
EFFECT: selective modulation of aberrant action of epigenetic enzymes has significant perspective for treating several diseases.
17 cl, 14 dwg, 4 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN EZH2 INHIBITORS AND METHODS FOR APPLICATION THEREOF | 2011 |
|
RU2765155C2 |
| HUMAN EZH2 INHIBITORS AND METHODS FOR USE THEREOF | 2013 |
|
RU2704445C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2013 |
|
RU2699546C2 |
| REPROGRAMMING OF EFFECTIVE PROTEIN INTERACTIONS FOR EPIGENETIC DEFECTS CORRECTION IN MALIGNANT TUMOUR | 2013 |
|
RU2637441C2 |
| METHODS OF TREATING CANCER | 2013 |
|
RU2677276C2 |
| ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2632193C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2012 |
|
RU2629118C2 |
| SALT FORM OF HUMAN HISTONE METHYLTRANSERASE EZH2 INHIBITOR | 2013 |
|
RU2658911C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2662436C2 |
| METHOD FOR NUCLEOSOMES ADDUCTS DETECTION | 2012 |
|
RU2634266C2 |
